Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- 18 June 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (7), 859-870
- https://doi.org/10.1016/s1470-2045(15)00050-9
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancerMolecular Aspects of Medicine, 2011
- HCC and angiogenesis: possible targets and future directionsNature Reviews Clinical Oncology, 2011
- Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinomaJournal of Clinical Pathology, 2011
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2Journal of Clinical Oncology, 2010
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular CarcinomaCancer Research, 2009
- Diagnosis of hepatocellular carcinomaWorld Journal of Gastroenterology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Staging systems in hepatocellular carcinomaHPB, 2005
- Clinical Characteristics and Prognosis of Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2000
- Long interval between HCV infection and development of hepatocellular carcinomaLiver International, 1995